In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach

被引:65
作者
Dorsthorst, DTAT
Verweij, PE
Meletiadis, J
Bergervoet, M
Punt, NC
Meis, JFGM
Mouton, JW
机构
[1] Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, NL-6532 SZ Nijmegen, Netherlands
[2] Medimat, Maastricht, Netherlands
[3] Catholic Univ Nijmegen, Ctr Med, Dept Med Microbiol, NL-6500 HC Nijmegen, Netherlands
关键词
D O I
10.1128/AAC.46.9.2982-2989.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Combination therapy could be of benefit for the treatment of invasive yeast infections. However, in vitro interaction studies are relatively scarce and the interpretation of the fractional inhibitory concentration (FIC) index can be contradictory due to various definitions used; not all information on the interaction study is used in the index, and different MIC end points exist for different classes of drugs. Fitting an interaction model to the whole response surface and estimation of an interaction coefficient alpha (ICalpha) would overcome these objections and has the additional advantage that confidence intervals of the interaction are obtained. The efficacy of flucytosine (5FC) in combination with amphotericin B (AB) and fluconazole (FCZ) was studied against 35 yeast isolates in triplicate (Candida albicans [n = 9], Candida glabrata [n = 9], Candida krusei [n = 9], and Cryptococcus neoformans [n = 8]) using a broth microdilution checkerboard method and measuring growth after 48 h by a spectrophotometer. The FIC index and ICalpha were determined, the latter by estimation from the response surface approach described by Greco et al. (W. R. Greco, G. Bravo, and J. C. Parsons, Pharmacol. Rev. 47:331-385, 1995) by using a computer program developed for that purpose. For the 5FC-FCZ combination, the interactions determined by the ICalpha generally were in concordance with the interactions determined by the FIC index, but large discrepancies were found between both methods for the 5FC-AB combination. These could mainly be explained by shortcomings in the FIC approach. The in vitro interaction of 5FC-AB demonstrated variable results depending on the tested Candida isolate. In general, the 5FC-FCZ combination was antagonistic against Candida species, but for some Candida isolates synergism was found. For C neoformans the interaction for both combinations was highly dependent on the tested isolate and the method used. Response surface approach is an alternative method for determining the interaction between antifungal agents. By using this approach, some of the problems encountered with the FIC were overcome.
引用
收藏
页码:2982 / 2989
页数:8
相关论文
共 21 条
  • [1] METHOD FOR TESTING FOR SYNERGY WITH ANY NUMBER OF AGENTS
    BERENBAUM, MC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1978, 137 (02) : 122 - 130
  • [2] FUNGAL-INFECTIONS IN CANCER-PATIENTS - AN INTERNATIONAL AUTOPSY SURVEY
    BODEY, G
    BUELTMANN, B
    DUGUID, W
    GIBBS, D
    HANAK, H
    HOTCHI, M
    MALL, G
    MARTINO, P
    MEUNIER, F
    MILLIKEN, S
    NAOE, S
    OKUDAIRA, M
    SCEVOLA, D
    VANTWOUT, J
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (02) : 99 - 109
  • [3] Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro
    Drusano, GL
    D'Argenio, DZ
    Symonds, W
    Bilello, PA
    McDowell, J
    Sadler, B
    Bye, A
    Bilello, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) : 2153 - 2159
  • [4] ROLE OF PHARMACOKINETICS IN THE OUTCOME OF INFECTIONS
    DRUSANO, GL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (03) : 289 - 297
  • [5] IN-VITRO DETERMINATION OF OPTIMAL ANTIFUNGAL COMBINATIONS AGAINST CRYPTOCOCCUS-NEOFORMANS AND CANDIDA-ALBICANS
    GHANNOUM, MA
    FU, Y
    IBRAHIM, AS
    MORTARA, LA
    SHAFIQ, MC
    EDWARDS, JE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (11) : 2459 - 2465
  • [6] Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
    Ghannoum, MA
    Rice, LB
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1999, 12 (04) : 501 - +
  • [7] GRECO WR, 1995, PHARMACOL REV, V47, P331
  • [8] CLINICAL ASPECTS OF FUNGAL INFECTION IN ORGAN TRANSPLANT RECIPIENTS
    HIBBERD, PL
    RUBIN, RH
    [J]. CLINICAL INFECTIOUS DISEASES, 1994, 19 : S33 - S40
  • [9] FLUCONAZOLE COMBINED WITH FLUCYTOSINE FOR TREATMENT OF CRYPTOCOCCAL MENINGITIS IN PATIENTS WITH AIDS
    LARSEN, RA
    BOZZETTE, SA
    JONES, BE
    HAGHIGHAT, D
    LEAL, MA
    FORTHAL, D
    BAUER, M
    TILLES, JG
    MCCUTCHAN, JA
    LEEDOM, JM
    [J]. CLINICAL INFECTIOUS DISEASES, 1994, 19 (04) : 741 - 745
  • [10] Lorian V., 1991, ANTIBIOTICS LAB MED, P432